查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916883

血流阻断胶囊市场：全球预测（2026-2032 年），依产品类别、剂型、治疗领域、包装规格及通路划分

Duanxueliu Capsule Market by Product Class, Dosage Strength, Therapeutic Area, Packaging Size, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，血液流动阻断胶囊市场价值为 5.4534 亿美元，预计到 2026 年将成长至 5.8502 亿美元，预计到 2032 年将达到 8.7654 亿美元，复合年增长率为 7.01%。

主要市场统计数据
基准年 2025 5.4534亿美元
预计年份：2026年 5.8502亿美元
预测年份：2032年 8.7654亿美元
复合年增长率 (%) 7.01%

一个涵盖临床定位、监管摩擦点和商业性槓桿的综合框架，这些因素共同影响心血管和血液治疗领域的产品应用。

段雪柳胶囊是心血管和血液疾病治疗领域的重点治疗选择，需要生产者、支付者和临床医生进行策略性合作。本执行摘要了影响该产品在治疗通路和分销网络中定位的最主要结构趋势、监管考虑和商业性优势。

技术创新、法规环境和供应链转型将如何影响胶囊治疗性介入的临床应用管道和商业策略

胶囊剂治疗方法的治疗和商业性格局正经历快速变革，其驱动力包括生产製造技术的创新、监管重点的演变以及医疗服务提供者和患者期望的改变。製剂科学和精准给药技术的进步正在降低产品差异化程度，并扩大安全性和耐受性方面的差异化潜力，这正在影响药物上市的讨论以及配药医生的选择。

2025年推出和调整的关税和贸易措施对药品原料的持续供应、价格谈判和策略采购决策产生了影响。评估供应链压力和采购调整。

2025年推出调整的关税及贸易措施再次引发人们对医药原料跨境供应链依赖性的关注。虽然关税对成品药的影响通常有限，但对原料药和中间体征收关税可能会增加依赖国际采购的活性成分和辅料的生产商的上游成本压力。

深入了解胶囊製剂的产品类别、剂型、治疗重点、包装和分销管道如何推动差异化的监管和商业策略。

细分市场分析揭示了不同产品类别、剂量强度、治疗领域、包装形式和分销管道在临床应用、通路策略和营运重点方面存在显着差异。鑑于非处方药和处方笺药产品类别之间的差异，监管文件、药物监测和支付方互动方面的要求也存在显着差异，因此需要製定不同的商业化蓝图。

美洲、欧洲、中东、非洲和亚太地区的区域趋势比较，这些趋势正在影响胶囊製剂的监管策略、采购管道和临床应用模式。

区域趋势对监管管道、采购实践和临床应用具有决定性影响，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，市场进入讨论通常聚焦于支付方的报销框架、真实世界疗效比较数据以及与心臟病学和血液病学诊疗路径的整合，这些因素共同指导着药品目录的编制和医院的采购决策。

竞争策略着重于证据生成、生产韧性和整合病人参与，以维持胶囊产品的差异化优势和长期市场地位。

胶囊剂治疗领域的企业竞争主要集中在透过临床证据、生产品质和完善的患者支持项目来实现差异化。主要企业投资于有针对性的临床研究，以证明其安全性和耐受性优势；而营运领导企业则加强了品质系统和供应链监控，以最大限度地降低批间差异和监管风险。

製造商可采取的切实可行的策略重点，以确保供应韧性、产生真实世界数据、优化包装和分销管道，并整合跨部门能力以实现永续获取。

产业领导者应优先考虑供应链多元化和本土化方案，以降低跨境关税波动和物流中断带来的风险。对关键活性成分实施双重采购策略，并合格的本地契约製造(CMO)，有助于企业在确保供应连续性的同时，遵守当地监管要求。

本研究采用混合方法研究框架，整合监管文件审查、临床註册分析、相关人员访谈和供应链图谱分析，以产生可操作且检验的研究结果。

我们的研究途径结合了对监管文件、临床试验註册资讯和公开药物监测摘要的系统性二手资料分析，以及对监管事务、采购、临床实践和供应链运营等关键相关人员的访谈。二级资讯来源提供了监管和临床背景信息，而一手研究检验了多个司法管辖区的运营实践、采购行为和分销渠道趋势。

简明扼要地总结了将临床潜力转化为不同医疗保健系统中患者持续获得医疗服务所需的营运要务和跨职能优先事项。

本执行摘要阐述了在心血管和血液疾病治疗中成功应用胶囊疗法所需的多方面考量。关键主题包括：生产和采购环节的韧性需求、上市后证据产生的重要性日益凸显，以及包装和分销策略与临床和医疗保险报销实际情况相符的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：血流切割胶囊市场（依产品类别划分）

  • 非处方药
  • 处方药

第九章 依剂型分類的血流阻断胶囊市场

  • 250毫克
  • 500毫克

第十章 依治疗领域分類的血流切割胶囊市场

  • 循环系统
  • 血液疾病

第十一章 依包装规格分類的血流切割胶囊市场

  • 10粒胶囊
  • 20粒胶囊
  • 30粒胶囊

第十二章 血流切割胶囊市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 血流切割胶囊市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 血流切割胶囊市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国血流切割胶囊市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国止血胶囊市场

第十七章：中国血流切割胶囊市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anhui Zhang Hengchun Pharmaceutical Co., Ltd.
  • Beijing Tong Ren Tang Co., Ltd.
  • China National Pharmaceutical Group Corporation（Sinopharm）
  • China Resources Sanjiu Medical & Pharmaceutical（Group）Co., Ltd.
  • Guizhou Hengba Pharmaceutical Co., Ltd.
  • Guizhou Xintuo Pharmaceutical Co., Ltd.
  • Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Jilin Dongbao Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Zhejiang Conba Pharmaceutical Co., Ltd.
Product Code: MRR-AE420CB153CE

The Duanxueliu Capsule Market was valued at USD 545.34 million in 2025 and is projected to grow to USD 585.02 million in 2026, with a CAGR of 7.01%, reaching USD 876.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 545.34 million
Estimated Year [2026] USD 585.02 million
Forecast Year [2032] USD 876.54 million
CAGR (%) 7.01%

Comprehensive framing of clinical positioning, regulatory friction points, and commercial levers that determine product adoption within cardiovascular and hematological care

Duanxueliu Capsule represents a focused therapeutic offering within cardiovascular and hematological care pathways that demands strategic attention from manufacturers, payers, and clinicians. This executive summary synthesizes the most salient structural dynamics, regulatory considerations, and commercial levers that influence how the product is positioned across treatment pathways and distribution networks.

Throughout the summary, the emphasis is on pragmatic insight rather than speculative projection. The analysis synthesizes observed regulatory approvals, prevailing clinical practice guidelines, supply chain realities, and patient access mechanisms that together shape uptake patterns. As a result, readers will gain a clear view of the operational priorities that stakeholders must address to convert clinical potential into sustained utilization.

Moreover, this introduction frames subsequent sections that examine transformative market shifts, tariff-related headwinds, product and channel segmentation, geographic differentials, competitive behaviors, recommended strategic actions, and the rigorous research approach used to compile these findings. Each section builds on empirical indicators and stakeholder intelligence to provide a coherent basis for informed decision-making.

How technological, regulatory, and supply chain transformations are reshaping clinical adoption pathways and commercial strategies for capsule-based therapeutic interventions

The therapeutic and commercial landscape for capsule-delivered therapies is undergoing rapid transformation driven by technology-enabled manufacturing, evolving regulatory priorities, and changing provider and patient expectations. Advances in formulation science and precision dosing have reduced variability and expanded the potential to differentiate products on safety and tolerability profiles, which in turn influences formulary discussions and prescriber preference.

Concurrently, digitization of medication management and telehealth adoption are altering how prescriptions are initiated, monitored, and refilled. These shifts accelerate the importance of channel optimization and patient-support solutions, and they create opportunities to capture adherence data that supports value-based contracting. In parallel, heightened scrutiny on supply chain resilience and quality oversight has pushed manufacturers to re-evaluate sourcing strategies for active ingredients and packaging inputs.

Finally, regulatory agencies have signaled greater emphasis on post-market evidence and pharmacovigilance, creating higher expectations for ongoing data generation. Taken together, these transformative shifts require integrated responses across clinical development, regulatory affairs, commercial operations, and manufacturing to sustain access and competitive differentiation.

Assessment of 2025 tariff-driven supply chain pressures and procurement adaptations that influenced continuity, pricing negotiations, and strategic sourcing decisions for pharmaceutical inputs

Tariff policies and trade measures introduced or adjusted in 2025 created renewed attention on cross-border supply chain dependencies for pharmaceutical inputs. While finished dosage forms often attract limited tariff exposure, tariffs applied to raw materials and intermediates can increase upstream cost pressure for manufacturers that rely on internationally sourced active pharmaceutical ingredients and excipients.

As a result, organizations with concentrated sourcing footprints experienced operational stress when logistics frictions and customs procedures amplified lead-time variability. Consequently, procurement teams accelerated supplier qualification and dual-sourcing initiatives to mitigate the risk of supply interruption. At the same time, regulatory-compliant domestic manufacturing capacity became a strategic priority for firms seeking to reduce exposure to trade policy volatility.

Importantly, tariff-related dynamics also influenced broader commercial conversations, including pricing negotiations with payers, contractual commitments to maintain uninterrupted supply, and decisions around inventory buffers. In response, companies prioritized transparent supplier mapping, stronger contractual protections with key vendors, and scenario planning that incorporated varying levels of cross-border tariff friction to preserve continuity of patient access.

Insights on product class, strength, therapeutic focus, packaging format, and distribution pathways that drive differentiated regulatory and commercial approaches for capsule therapies

Segmentation analysis reveals meaningful heterogeneity in clinical usage, channel strategies, and operational priorities across product class, dosage strength, therapeutic focus, packaging, and distribution pathways. When considering product class differences between over-the-counter availability and prescription-only designation, the requirements for regulatory documentation, pharmacovigilance, and payer interaction shift substantially, demanding divergent commercialization roadmaps.

Dosage strength differentiation between lower-strength and higher-strength capsule presentations affects clinical positioning and prescriber routing, with implications for labeling, dosing guidance, and interchangeability discussions. Therapeutic area distinctions between cardiovascular and hematological indications also shape evidence needs: cardiovascular applications frequently require long-term safety monitoring and outcomes-oriented data, whereas hematological indications may necessitate targeted clinical endpoints and specialist engagement.

Packaging size choices ranging from smaller blister counts to larger multi-unit packs influence adherence, cost per dispensing event, and reimbursement coding, while distribution channel strategy across hospital pharmacies, online pharmacies, and retail pharmacies determines stocking cadence, promotional tactics, and patient support workflows. Taken together, these segmentation dimensions underscore the importance of aligning regulatory, clinical, and commercial tactics to the specific product profile and route to patient.

Comparative regional dynamics across the Americas, Europe-Middle East-Africa, and Asia-Pacific that shape regulatory strategy, procurement pathways, and clinical adoption patterns for capsule therapeutics

Regional dynamics exert a decisive influence on regulatory pathways, procurement practices, and clinical adoption, with distinct patterns emerging across the Americas, Europe-Middle East-Africa, and Asia-Pacific. In the Americas, market access conversations frequently center on payer reimbursement frameworks, real-world evidence for comparative effectiveness, and integration with cardiology and hematology care pathways, which together guide formulary placement and hospital procurement decisions.

In the Europe-Middle East-Africa region, regulatory heterogeneity and centralized versus decentralized approval mechanisms require nuanced regulatory strategies and local evidence generation to satisfy national agencies and major hospital systems. Additionally, procurement consortiums and tenders in parts of this region create different commercial timelines and contractual structures that manufacturers must anticipate.

Asia-Pacific exhibits a diverse set of regulatory maturities and manufacturing capabilities, and many markets emphasize local clinical validation and price controls as conditions of market entry. Moreover, regional supply chain hubs and manufacturing ecosystems in Asia-Pacific have implications for sourcing, cost structures, and lead times for global product programs. Across all regions, tailoring engagement strategies to local payer expectations, provider behaviors, and regulatory requirements is essential for consistent access and sustained uptake.

Competitive strategies emphasizing evidence generation, manufacturing resilience, and integrated patient engagement that sustain differentiation and long-term positioning for capsule products

Competitive behavior among companies active in capsule therapeutics centers on differentiating through clinical evidence, manufacturing quality, and integrated patient support programs. Leading firms invest in targeted clinical studies that demonstrate safety and tolerability advantages, while operational leaders strengthen quality systems and supply chain oversight to minimize batch variability and regulatory risk.

Strategic partnerships and contract manufacturing relationships have become common levers for scaling production without incurring the full capital burden of new facilities. At the same time, commercialization teams focus on multichannel engagement models that connect hospital pharmacists, specialist prescribers, and retail and digital dispensing partners to streamline initiation and refill adherence. Furthermore, companies are increasingly attentive to lifecycle management opportunities such as optimized dosing regimens, patient-centric packaging, and incremental formulation improvements that extend the therapeutic relevance of capsule products.

Taken together, these competitive priorities emphasize an integrated approach that combines robust evidence generation, resilient manufacturing and procurement strategies, and proactive commercial engagement to maintain long-term positioning in therapeutic categories characterized by clinical complexity and payer scrutiny.

Actionable strategic priorities for manufacturers to secure supply resilience, generate real-world evidence, optimize packaging and channels, and align cross-functional capabilities for sustainable access

Industry leaders should prioritize supply chain diversification and onshoring options to reduce exposure to cross-border tariff shocks and logistics disruptions. By implementing dual-sourcing strategies for key active ingredients and qualifying regional contract manufacturers, organizations can preserve continuity of supply while maintaining compliance with local regulatory requirements.

In parallel, companies must accelerate post-market evidence collection and leverage real-world data streams to substantiate comparative effectiveness and long-term safety. This evidence supports constructive payer dialogues and can enable innovative contracting approaches tied to outcomes. Additionally, optimizing packaging sizes and refill paradigms to align with clinical dosing patterns and patient adherence behaviors will improve persistence and reduce medication wastage.

Commercially, expanding digital dispensing partnerships and strengthening hospital pharmacy engagement will create more predictable channels for initiation and refill management. Finally, cross-functional alignment between regulatory, medical affairs, and commercial teams is essential to translate clinical differentiation into streamlined market access pathways and durable uptake among prescribers and patients.

Mixed-methods research framework integrating regulatory document review, clinical registry analysis, stakeholder interviews, and supply chain mapping to produce actionable and verifiable insights

The research approach combined systematic secondary analysis of regulatory filings, clinical trial registries, and publicly available pharmacovigilance summaries with primary stakeholder interviews across regulatory affairs, procurement, clinical practice, and supply chain operations. Secondary sources provided the regulatory and clinical context, while primary engagements validated operational realities, procurement behaviors, and channel dynamics in multiple jurisdictions.

Analytical rigor was maintained through triangulation of documentary evidence, stakeholder insights, and supply chain mapping to identify areas of risk and opportunity. Where appropriate, scenario-based sensitivity checks were used to test the resilience of strategic recommendations against plausible changes in trade policy, manufacturing disruptions, or shifts in provider preference. All qualitative inputs were coded thematically and synthesized to preserve nuance while ensuring actionable clarity.

Finally, ethical standards and confidentiality protocols governed all primary interviews, and findings were contextualized to reflect jurisdictional regulatory differences and clinical practice variations. This mixed-methods approach ensures that conclusions are both evidence-based and operationally relevant for decision-makers across development, manufacturing, and commercial functions.

Concise synthesis of operational imperatives and cross-functional priorities required to convert clinical promise into sustained patient access across diverse healthcare systems

This executive summary underscores the multifaceted considerations required to support successful deployment of capsule therapeutics in cardiovascular and hematological care. Key themes include the imperative for manufacturing and sourcing resilience, the growing importance of post-market evidence generation, and the need to align packaging and channel strategies with clinical and reimbursement realities.

Importantly, regulatory heterogeneity across regions and heightened attention to pharmacovigilance require proactive planning and sustained investment in quality systems and evidence collection. Companies that integrate these operational priorities with focused commercial engagement and digital-enabled patient support are positioned to navigate access barriers and enhance long-term utilization.

In conclusion, translating clinical promise into sustained patient access demands coordinated action across R&D, regulatory, manufacturing, and commercial teams. The insights presented here provide a foundation for pragmatic decision-making and targeted investments that reduce execution risk and improve the likelihood of consistent therapeutic availability across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duanxueliu Capsule Market, by Product Class

  • 8.1. Otc
  • 8.2. Prescription

9. Duanxueliu Capsule Market, by Dosage Strength

  • 9.1. 250 Mg
  • 9.2. 500 Mg

10. Duanxueliu Capsule Market, by Therapeutic Area

  • 10.1. Cardiovascular
  • 10.2. Hematological Disorders

11. Duanxueliu Capsule Market, by Packaging Size

  • 11.1. 10 Capsules
  • 11.2. 20 Capsules
  • 11.3. 30 Capsules

12. Duanxueliu Capsule Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Duanxueliu Capsule Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duanxueliu Capsule Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duanxueliu Capsule Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Duanxueliu Capsule Market

17. China Duanxueliu Capsule Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anhui Zhang Hengchun Pharmaceutical Co., Ltd.
  • 18.6. Beijing Tong Ren Tang Co., Ltd.
  • 18.7. China National Pharmaceutical Group Corporation (Sinopharm)
  • 18.8. China Resources Sanjiu Medical & Pharmaceutical (Group) Co., Ltd.
  • 18.9. Guizhou Hengba Pharmaceutical Co., Ltd.
  • 18.10. Guizhou Xintuo Pharmaceutical Co., Ltd.
  • 18.11. Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.
  • 18.12. Jiangsu Kanion Pharmaceutical Co., Ltd.
  • 18.13. Jilin Dongbao Pharmaceutical Co., Ltd.
  • 18.14. Tasly Pharmaceutical Group Co., Ltd.
  • 18.15. Yunnan Baiyao Group Co., Ltd.
  • 18.16. Zhejiang Conba Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUANXUELIU CAPSULE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DUANXUELIU CAPSULE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 250 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 500 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 10 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 20 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY 30 CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GCC DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. GCC DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. GCC DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 103. GCC DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. G7 DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. G7 DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 120. G7 DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 121. G7 DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NATO DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NATO DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. NATO DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. NATO DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DUANXUELIU CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA DUANXUELIU CAPSULE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY PRODUCT CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY PACKAGING SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA DUANXUELIU CAPSULE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)